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ABSTRACT
The susceptibilities of 40 clinical isolates of Aspergillus spp. (Aspergillus fumigatus, Aspergillus flavus,
Aspergillus niger, Aspergillus terreus) were determined for posaconazole and voriconazole by the CLSI
M38-A and EUCAST-AFST broth dilution methods. Where a discrepancy was observed between the
methods, the EUCAST method tended to give higher MIC values. Overall, the level of agreement was
92.5% and the intra-class correlation coefficient was > 0.90.
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INTRODUCTION
The European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) is a standing com-
mittee organised by the European Society of
Clinical Microbiology and Infectious Diseases
(ESCMID) and the national breakpoint commit-
tees of Europe. EUCAST was set up to harmonise
breakpoints of antimicrobial agents and to stand-
ardise susceptibility testing in Europe so that
comparable results and interpretations, both in
clinical practice and in antimicrobial resistance
surveillance, can be achieved. EUCAST has
tasked the Subcommittee on Antifungal Suscep-
tibility Testing (EUCAST-AFST) with preparing
guidelines for testing antifungal agents against
various fungal species.
EUCAST-AFST has already developed a stand-
ard broth microdilution procedure for the deter-
mination of antifungal MICs for fermentative
species of yeasts (document E.Dis.7.1) [1]. This
standard is based on the reference procedure
described in document M27-A2 by the CLSI,
formerly the NCCLS [2]. In addition, EUCAST-
AFST has developed a method for determining
broth dilution MICs for Aspergillus spp. This is a
microdilution method that is intended to produce
concordant results with the CLSI reference meth-
od for antifungal susceptibility testing of filamen-
tous fungi (document M38-A) [3]. The EUCAST
method includes some modifications based on
previous studies: (1) RPMI-1640 medium supple-
mented with glucose 2% w ⁄ v (RPMI 2% G) is
used as the assay medium; (2) the inoculum is
prepared by counting conidia in a haemacyto-
meter; and (3) an inoculum size of 1 · 105 to
5 · 105 conidia ⁄mL is used [4–6].
The agreement and correlation between the
various methods has not been evaluated previ-
ously for any antifungal agent. The aim of the
present study was to investigate the concordance
obtained between the CLSI and EUCAST standard
methods when determining the MICs of voricon-
azole and posaconazole for clinical isolates of
Aspergillus spp.
MATERIALS AND METHODS
Test isolates
A panel of 40 clinical isolates belonging to four different
Aspergillus spp. (ten each of Aspergillus fumigatus, Aspergillus
flavus, Aspergillus niger and Aspergillus terreus) was used. The
isolates were stored at ) 70C and were subcultured twice on
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potato dextrose agar slants at 35C for 2–3 days before testing.
Two reference strains, Candida krusei ATCC 6258 and Candida
parapsilosis ATCC 22019, were included as quality controls,
with MICs being within the accepted limits by both methods
on all occasions [7].
Antifungal agents
Posaconazole (Schering-Plough, Kenilworth, NJ, USA) and
voriconazole (Pfizer, New York, NY, USA) were provided in
the form of powders. Both drugs were dissolved in 100%
dimethylsulphoxide to make stock solutions of 3.2 g ⁄L, which
were stored at ) 70C until required. The range of posacona-
zole and voriconazole concentrations tested was from 0.015 to
8 mg ⁄L.
EUCAST broth dilution method
The assay medium used was RPMI-1640 (Sigma-Aldrich,
Stockholm, Sweden), with glutamine but without bicarbonate,
buffered to pH 7.0 with 0.165 M morpholinopropanesulphonic
acid (Sigma-Aldrich) and supplemented with glucose 2%w ⁄v.
Culture medium was prepared as a double-strength solution
and sterilised by filtration. Both drugs were diluted in the
assay medium, dispensed into flat-bottomed microdilution
trays (Corning Costar Europe, Badhoevedorp, The Nether-
lands) and frozen at ) 70C until required. The plates con-
tained 100 lL of two-fold serial dilutions of the drugs. Two
drug-free medium wells for growth and sterility controls were
used.
Inoculum suspensions were prepared by covering the
surface of Aspergillus colonies with 5 mL of sterile water
containing Tween-20 0.1% v ⁄v and probing with a sterile loop.
The conidia were transferred to a sterile tube, shaken vigor-
ously, and then adjusted by microscopic enumeration with a
cell-counting haemacytometer to provide a suspension of
1 · 106 to 5 · 106 conidia ⁄mL [4]. These suspensions were
diluted 1:10 in water, and each well was inoculated with
100 lL of the corresponding conidial inoculum suspension.
CLSI reference method
Susceptibility testing was performed by following the CLSI
M38-A guidelines [3]. Dilutions of both antifungal agents were
prepared with RPMI-1640 medium that was buffered to pH 7.0
with morpholinopropanesulphonic acid. The drug dilutions
were dispensed into round-bottomed microdilution plates
(Corning Costar) and frozen at ) 70C until required. The
conidial inoculum suspensions were adjusted to an optical
density of 80–82%, and diluted 1:50 in RPMI; each well was
then inoculated with 100 lL of the corresponding suspension.
Endpoint determination by EUCAST and CLSI procedures
MIC endpoints were defined for both drugs as the lowest drug
concentration that caused 100% growth inhibition. The MIC
readings were performed with the aid of a concave mirror after
incubation for 48 h at 35C. All experiments were repeated
twice on different days.
Analysis of results
Both on-scale and off-scale results were included in the
analysis. The reproducibility between the EUCAST and CLSI
results was calculated by determining the percentage of
agreement between MICs. Agreement was defined as discrep-
ancies between MICs of no more than ± 2 dilutions. In
addition, the correlation between the two sets of results was
calculated by using the intra-class correlation coefficient (ICC),
which was expressed to a maximum value of 1 with a 95% CI.
In order to approximate a normal distribution, the MICs were
transformed to log2 values, with p < 0.01 considered to be of
statistical significance. The ICC is a reverse measurement of
the variability in the counting values. All statistical analyses
were performed with SPSS software v.13.0 (SPSS Inc., Madrid,
Spain).
RESULTS
MIC data
The MIC ranges and geometric means obtained
by the CLSI and EUCAST methods for posacon-
azole and voriconazole against 40 Aspergillus spp.
isolates are summarised in Table 1. All the iso-
lates tested grew well both in round-bottomed
(CLSI) and flat-bottomed (EUCAST) microtitre
plates, giving detectable endpoints within 48 h. A
broad range of on-scale MICs was observed with
both antifungal agents. A. niger was the most
susceptible species, while A. flavus had higher
Table 1. Posaconazole and voricon-
azole susceptibilities of 40 isolates of
Aspergillus spp. as determined by
the CLSI and EUCAST broth micro-
dilution methodsSpecies Method
MIC (mg ⁄L)
Posaconazole Voriconazole
Range Geometric mean Range Geometric mean
A. fumigatus CLSI 0.015–1 0.08 0.06–1 0.52
EUCAST 0.03–1 0.12 0.25–2 0.66
A. flavus CLSI 0.015–0.25 0.11 1–2 1.36
EUCAST 0.125–1 0.24 1–2 1.74
A. niger CLSI 0.015–0.25 0.04 0.03–2 0.48
EUCAST 0.015–0.25 0.08 0.125–2 0.57
A. terreus CLSI 0.015–0.125 0.04 0.5–1 0.90
EUCAST 0.06–0.125 0.08 1–2 1.36
CLSI, Clinical Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Suseptibility
Testing.
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geometric mean MICs of both voriconazole and
posaconazole than did the other species. Discrep-
ancies between the two methods were reflected
mainly in higher MIC values obtained by the
EUCAST method compared with the CLSI meth-
od. However, the average increment was only
about a two-fold dilution and was statistically
insignificant.
Agreement between the methods
The percentages of agreement and ICC values
between the two methods for each Aspergillus sp.
and both antifungal agents are summarised in
Tables 2 and 3. Overall agreement was 92.5% by
drug and by organism. Thus, the general levels of
agreement were high, and were similar for the
different Aspergillus spp. tested, although a lower
level of agreement was observed for A. flavus.
Overall, the ICCs were also high (> 0.90), and
were statistically significant for all Aspergillus spp.
On analysis by antifungal agent, voriconazole
showed better agreement than posaconazole.
DISCUSSION
This study reports a comparison between the
MICs obtained by the CLSI and EUCAST meth-
ods for voriconazole and the new triazole posac-
onazole with clinical isolates of Aspergillus spp.
The proposed EUCAST standard for testing As-
pergillus spp. is a microdilution method, based on
the CLSI reference method for antifungal suscep-
tibility testing of filamentous fungi, but includes
modifications such as a higher inoculum size and
glucose concentration. Denning et al. [5] demon-
strated that inoculum sizes higher than those
proposed by the CLSI M38-A document (1 · 104
to 5 · 104 conidia ⁄mL) generate reproducible in-
vitro susceptibility data for Aspergillus spp., and
were able to identify in-vitro test conditions that
consistently differentiated Aspergillus strains
resistant in vivo from susceptible strains. The
former strains had high itraconazole MICs, and
no benefit was obtained in a murine model,
compared with untreated controls, when mice
were treated with different doses of itraconazole.
Gomez-Lopez et al. [6] did not find significant
MIC differences using RPMI or RPMI supple-
mented with glucose, and MIC values were not
elevated falsely, even if an inoculum size of
105 conidia ⁄mL was used. Other studies have
reported no effect on the growth rate of Asperg-
illus spp. when RPMI is supplemented with
glucose 2% w ⁄ v, even after incubation for 100 h
[8].
With respect to inoculum preparation, a previ-
ous study in three laboratories [4] evaluated the
counting of conidia in a haemacytometer as a
means of inoculum preparation for susceptibility
testing of Aspergillus spp., and was able to
demonstrate that inoculum preparation by this
method was an accurate and universal procedure,
independent of the colour and size of conidia.
Moreover, this method was more reliable and
reproducible than preparation by spectrophoto-
metric adjustment at 530 nm [9].
Nevertheless, minor variations in test para-
meters can have a significant influence on MIC
values, and should be analysed in detail before
implementation in routine clinical laboratories.
Previous reports have shown that modifications
did not have a significant influence on MICs of
amphotericin B or itraconazole [10], indicating
that MICs obtained by the CLSI reference method
are comparable with those achieved by the pro-
posed EUCAST standard method. MICs obtained
in the present study by the EUCAST method were
consistently, but not significantly, higher than
MICs obtained by the CLSI method, which might
be explained by the larger inoculum size used in
the EUCAST method. Even so, agreement and
concordance between the two methods were high
and statistically significant. Thus, the results of
Table 2. Agreement and intra-class correlation coefficient
(ICC) between the CLSI and EUCAST broth microdilution
methods for different Aspergillus spp.
Species % Agreement ICC (90% CI)
A. fumigatus 97.5 0.94 (0.89–0.97)
A. flavus 87.5 0.92 (0.85–0.96)
A. niger 90.0 0.93 (0.87–0.96)
A. terreus 93.3 0.97 (0.94–0.98)
CLSI, Clinical Laboratory Standards Institute; EUCAST, European Committee on
Antimicrobial Suseptibility Testing.
Table 3. Agreement and intra-class correlation coefficient
(ICC) between the CLSI and EUCAST broth microdilution
methods for posaconazole and voriconazole
Antifungal agent % Agreement ICC (95% CI)
Posaconazole 86.3 0.82 (0.73–0.87)
Voriconazole 98.8 0.90 (0.83–0.93)
CLSI, Clinical Laboratory Standards Institute; EUCAST, European Committee on
Antimicrobial Suseptibility Testing.
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this work demonstrate that susceptibility results
obtained by the two methods are comparable, and
that the EUCAST method for susceptibility testing
of Aspergillus spp. is potentially a reliable tech-
nique for use in the routine clinical laboratory.
Multicentre studies should be performed to
confirm these results.
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